What is MANE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 4.86B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MANE?

P/E (TTM) is n/a and 52-week range is $32.00 to $136.72 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MANE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MANE?

The company profile lists net income (TTM) near $-158M, EPS (TTM) near $-3.78 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Veradermics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New Haven, Connecticut, US, 41.8M shares outstanding, ISIN US9229671048 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Veradermics Inc

$MANE

Health Care · Pharmaceuticals

Run Scenarios

$116.26

-5.02%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. The company is headquartered in New Haven, Connecticut and currently employs 21 full-time employees. The company went IPO on 2026-02-04. The firm is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The firm is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The firm is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

Employees

Website

www.veradermics.com/

IPO

2026-02-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)